miR-137–LAPTM4B regulates cytoskeleton organization and cancer metastasis via the RhoA-LIMK-Cofilin pathway in osteosarcoma
Ruyu Yan,
Dan Liu,
Junjie Wang,
Minxia Liu,
Hongjuan Guo,
Jing Bai,
Shuo Yang,
Jun Chang,
Zhihong Yao,
Zuozhang Yang,
Tomas Blom,
Kecheng Zhou
Affiliations
Ruyu Yan
School of Life Sciences, Anhui Medical University
Dan Liu
School of Life Sciences, Anhui Medical University
Junjie Wang
School of Life Sciences, Anhui Medical University
Minxia Liu
School of Life Sciences, Anhui Medical University
Hongjuan Guo
School of Life Sciences, Anhui Medical University
Jing Bai
School of Life Sciences, Anhui Medical University
Shuo Yang
Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University
Jun Chang
Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University
Zhihong Yao
Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center)
Zuozhang Yang
Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center)
Tomas Blom
Department of Anatomy, Faculty of Medicine, University of Helsinki
Abstract Osteosarcoma (OS) is a rare malignant bone tumor but is one leading cause of cancer mortality in childhood and adolescence. Cancer metastasis accounts for the primary reason for treatment failure in OS patients. The dynamic organization of the cytoskeleton is fundamental for cell motility, migration, and cancer metastasis. Lysosome Associated Protein Transmembrane 4B (LAPTM4B) is an oncogene participating in various biological progress central to cancer biogenesis. However, the potential roles of LAPTM4B in OS and the related mechanisms remain unknown. Here, we established the elevated LAPTM4B expression in OS, and it is essential in regulating stress fiber organization through RhoA–LIMK–cofilin signaling pathway. In terms of mechanism, our data revealed that LAPTM4B promotes RhoA protein stability by suppressing the ubiquitin-mediated proteasome degradation pathway. Moreover, our data show that miR-137, rather than gene copy number and methylation status, contributes to the upregulation of LAPTM4B in OS. We report that miR-137 is capable of regulating stress fiber arrangement, OS cell migration, and metastasis via targeting LAPTM4B. Combining results from cells, patients’ tissue samples, the animal model, and cancer databases, this study further suggests that the miR-137–LAPTM4B axis represents a clinically relevant pathway in OS progression and a viable target for novel therapeutics.